Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - 90 mg - ticagrelor 90 mg

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - atenolol; chlorthalidone - tablet, film coated - 50 mg - atenolol 50 mg; chlorthalidone 12.5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - water for injections -

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - candesartan cilexetil; hydrochlorothiazide - tablet - 16 mg - candesartan cilexetil 16 mg; hydrochlorothiazide 12.5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; water for injections; citric acid; sodium citrate dihydrate; sodium hydroxide - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - sodium chloride, quantity: 200 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indications as at 19 february 1993 : as an additive to parenteral fluids in patients who have specific electrolyte needs. as a sclerosing agent for small symptomatic varicose veins.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - neostigmine methylsulfate -

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 90mg;  ;  ;   - film coated tablet - 90 mg - active: ticagrelor 90mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide yellow macrogol 400 magnesium stearate mannitol purified talc purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.